View in EDS

miR-21-5p dysregulation is associated with gut microbiota dysbiosis and pro-oncogenic markers in primary sclerosing cholangitis with concomitant inflammatory bowel disease.

Saved in:
Bibliographic Details
Title: miR-21-5p dysregulation is associated with gut microbiota dysbiosis and pro-oncogenic markers in primary sclerosing cholangitis with concomitant inflammatory bowel disease.
Authors: Santos AA; Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Portugal. Electronic address: afasantos@ff.ulisboa.pt., Pires D; CIIS - Centro de Investigação Interdisciplinar em Saúde, Faculdade de Medicina, Universidade Católica Portuguesa, Lisboa, Portugal., Marques V; Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Portugal., Alesina N; Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Portugal., Rodrigues PM; Department of Liver and Gastrointestinal Diseases, Biogipuzkoa Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain; Ikerbasque, Basque Foundation for Science, Bilbao, Spain; Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, Madrid, Spain., Bravo AC; Division of Gastroenterology, Hospital Beatriz Ângelo, Loures, Portugal., Gouveia C; Division of Gastroenterology, Hospital Beatriz Ângelo, Loures, Portugal., Saraiva S; Division of Gastroenterology, Hospital Beatriz Ângelo, Loures, Portugal., Correia L; Division of Gastroenterology, ULS Santa Maria, Lisboa, Portugal., Crespo R; Division of Gastroenterology, Hospital Lusíadas, Lisboa, Portugal., da Silva JP; Division of Gastroenterology, Hospital Lusíadas, Lisboa, Portugal., Cravo M; Division of Gastroenterology, Hospital da Luz, Lisboa, Portugal., Banales JM; Department of Liver and Gastrointestinal Diseases, Biogipuzkoa Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain; Ikerbasque, Basque Foundation for Science, Bilbao, Spain; Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, Madrid, Spain; Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain., Torres J; Division of Gastroenterology, Hospital Beatriz Ângelo, Loures, Portugal; Division of Gastroenterology, Hospital da Luz, Lisboa, Portugal; Faculdade de Medicina, Universidade de Lisboa, Portugal., Rodrigues CMP; Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Portugal.
Source: Experimental and molecular pathology [Exp Mol Pathol] 2026 Mar; Vol. 145, pp. 105013. Date of Electronic Publication: 2025 Dec 05.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 0370711 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-0945 (Electronic) Linking ISSN: 00144800 NLM ISO Abbreviation: Exp Mol Pathol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1096-0945
DOI:10.1016/j.yexmp.2025.105013